Board-Certified ICU Pharmacist Care Linked to Lower Mortality

This large multicenter observational analysis suggests that exclusive daily care by board-certified critical care pharmacists is independently associated with reduced ICU patient mortality and faster discharge alive.

📅 Journal publication: Jul 2026 · Last updated: Oct 12, 2026

★ Must Readcritical care pharmacistboard certificationBCCCPBCPSICU mortalityhazard of discharge alivecomprehensive medication managementobservational studyOPTIMpharmacy workforce Critical Care / ICU

Also in Clinical Practice

Background Information

Board-certified pharmacists improve ICU patient outcomes.

The study examines the impact of pharmacist board certification on outcomes in critically ill patients, highlighting potential improvements in mortality and discharge rates. Board-certified pharmacists (BCPs) were associated with reduced mortality (OR 0.80, 95% CI 0.69-0.92) and increased ICU (HR 1.08, 95% CI 1.03-1.13) and hospital discharge rates (HR 1.19, 95% CI 1.13-1.26). Findings suggest board certification of CCPs is a modifiable factor that can improve patient outcomes in the ICU. The study is robust with a large sample size across multiple institutions. Daily care by board-certified pharmacists may enhance mortality and discharge outcomes in ICU patients.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Smith SE, Henry K, Heavner MS, Keedy C, Duong H, Chen Z, Chen X, OPTIM Investigator Team, Sikora A

Citation: Smith SE, Henry K, Heavner MS, et al. Impact of Pharmacist Board Certification on Health Outcomes of Critically Ill Patients: An Analysis of the Optimizing Pharmacist-Team Integration for ICU Patient Management (OPTIM) Study. Journal of the American College of Clinical Pharmacy : JACCP. 2026;9(7):e70258. doi:10.1002/jac5.70258

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →